Skip to content
Parakho

Onesource Specialty Pharma Ltd

NSE ONESOURCEBSE 544292onesourcecdmo.com

Q1 FY27, unaudited

Revenue
₹446.47 Cr
Profit after tax
₹51.23 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations446.47+39.08%1,405.38
Other income3.79−27.94%15.01
Total income450.26+38.00%1,420.39
Employee benefit expense68.39+17.61%240.45
Finance costs30.52+12.90%120.58
Depreciation & amortisation36.18+8.69%136.80
Total expenses399.03+32.37%1,393.76
Profit before tax51.23+106.43%21.21
Tax expense0.00—0.00
Profit after tax51.23+106.43%21.21
Total comprehensive income51.23+106.43%21.67
Earnings per share
Earnings per share, basic₹4.47₹1.85
Earnings per share, diluted₹4.47₹1.85

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q4 FY26

OneSource reported a sequential recovery in Q4 FY26 with revenue of INR4,282 million, up 47% quarter-over-quarter, driven by the India Semaglutide launch and broad-based improvement across service lines. EBITDA rose more than 5x sequentially to INR919 million, while full-year revenue declined 2% and EBITDA declined about 35% year-on-year due to delayed Semaglutide approvals in Canada earlier in the year. Management reiterated its FY28 guidance of US$400 million organic revenue with around 40% EBITDA margin and confirmed the Steriscience/Brooks scheme has been deferred following shareholder concerns on valuation.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 25 Sept 2026.